Lung cancer prognosis has traditionally been determined by tumour burden. For decades, the principal determinant of outcome after surgical resection has been pathological stage, defined according to the International Association for the Study of Lung Cancer tumour-node-metastasis classification, now in its ninth edition.1 More recently, precision oncology has transformed patient management further through molecular tumour profiling, predictive biomarkers and targeted or immunotherapies. Landmark studies such as ADAURA have established adjuvant osimertinib as standard treatment for resected Epidermal Growth Factor Receptor (EGFR)-mutant non-small cell lung cancer (NSCLC),2 while CheckMate-816 has demonstrated the benefit of neoadjuvant immunotherapy and chemotherapy in resectable NSCLC.3 Tumour biology increasingly determines treatment decisions and prognosis.

Despite this progress, precision medicine has remained largely tumour-centric. Patient characteristics including pulmonary function, performance status, frailty and comorbidity have been used to determine fitness for treatment rather than long-term prognosis. As our understanding of tumour biology…